BHV-7000

Biohaven's investigational drug BHV-7000 failed to demonstrate statistical significance in meeting the Young Mania Rating Scale primary endpoint in a Phase II/III bipolar disorder trial.

Biohaven's NDA resubmission for troriluzole in spinocerebellar ataxia shows promise, with a 60% probability of success and potential peak sales exceeding $1 billion.

Biohaven's BHV-7000 demonstrates excellent tolerability in Phase 1 trials, with no CNS adverse effects typically associated with anti-seizure medications.

BHV-7000, a novel drug activating potassium channels, is under clinical trial for focal onset epilepsy, offering a new approach for drug-resistant cases.

Early-stage data on mivelsiran, an RNA therapeutic, shows encouraging results for treating patients with early Alzheimer's disease.